The results were statistically significant and the effect size (Cohen’s d values) of both treatment ... reported in treatment groups was mild-to-moderate drowsiness. No deaths were reported.

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

FROM nausea to constipation, we’ve all heard about the possible brutal side effects of fat jabs – but how familiar are you ...

Mounting cost and feasibility concerns have spurred an upstate Assemblymember to propose a revamp of New York’s electric school bus transition.

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with ...

A study published today by PLOS One found that patients prescribed medicinal marijuana experienced sustained improvements in ...

Paired t-tests confirmed these gains (p 0.005), with large and moderate effect sizes (Cohen’s d = 0.87, 0.59). Moreover, civil protection and risk management competencies saw increases of over 70% (p ...

We used random effects models to calculate pooled Cohen's d effect size estimates for the patient knowledge and patient experience outcome domains. Conclusions BR have been implemented in a variety of ...